Merck Eyes $28-32 Billion Deal for Cancer Drugmaker Revolution Medicines
Merck negotiates potential acquisition of Revolution Medicines for up to $32B, seeking new cancer treatments as Keytruda patent expiration looms in 2028.
/ 15 items
#RVMD↓
Immuneering's Pancreatic Cancer Data Fails to Impress: Stock Plunges 23% Despite Survival Claims
Immuneering (IMRX) reports 64% survival rate for Atebimetinib in pancreatic cancer trial, but shares plunge 23% as investors remain unconvinced about cross-trial comparisons and competitive threats.
AbbVie Denies Acquisition Talks with Revolution Medicines Despite WSJ Report
AbbVie denies reports of buying Revolution Medicines after Wall Street Journal claimed advanced talks.
Major Biotech Upgrades and Coverage Initiations: Regeneron, Erasca, Protara, Design Therapeutics, Oric
Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities.
FDA Grants Orphan Drug Status to Pancreatic Cancer Treatment Daraxonrasib
Revolution Medicines' daraxonrasib receives FDA Orphan Drug Designation for pancreatic cancer treatment, offering hope for patients with limited options in this deadly disease.
Revolution Medicines Receives FDA Priority Voucher for Cancer Drug Daraxonrasib
Revolution Medicines awarded FDA National Priority Voucher for daraxonrasib (RMC-6236), a breakthrough RAS inhibitor targeting pancreatic and lung cancer in Phase 3 trials.